A recent study led by Dr. Philip J. Mease examined the factors contributing to biologic therapy switching among patients with psoriasis and psoriatic arthritis. Using data from the CorEvitas Psoriasis Registry, the study identified key drivers, including high Psoriasis Area and Severity Index (PASI) scores, poor quality of life, and significant joint pain. Tune in to learn more about these findings and their implications for patient care with Dr. Mease, Director of Rheumatology Research at Providence Swedish Medical Center and Clinical Professor at the University of Washington.